StudyReason for exclusiona
Anandarajah AP, Ritchlin CT. Etanercept in psoriatic arthritis. Expert Opin Biol Ther 2003;3(1):169–77.2
Antoni CE. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) (errata). Arthritis Rheum 2005;52(9):2951.2
Bathon J, Fleischmann R, Peloso P, Chon Y, Hooper M, Lin SL. Rates of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials. Arthritis Rheum 2006;54(Suppl. 9):188.2
Bongiorno MR, Pistone G, Doukaki S, Arico M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol Ther 2008;21(Suppl. 2):15–20.2
Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR 50 response after 24 weeks of treatment. Scand J Rheumatol 2008;37(5):399–400.2
Colombel JF. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. Expert Rev Gastroenterol Hepatol 2008;2(2):163–76.2
Cruyssen BV, De Keyser F, Kruithof E, Mielants H, Van den Bosch F. Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis 2006;65(Suppl. 2):546–7.2
Frankel EH, Strober BE, Crowley JJ, Fivenson DP, Woolley JM, Yu EB, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007;79(4):322–6.2
Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. J Dermatolog Treat 2006;17(6):343–52.2
Hamza S, Chon Y, Hooper M, MacPeek D, Lin S. Rates of serious infectious events and opportunistic infections in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials. Ann Rheum Dis 2007;66(Suppl. 2):171–2.2
Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Pharmd EBY, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol 2007;6(3):299–306.2
Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67(3):364–9.2
Kvien TK, Heiberg MS, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(Suppl. 39):188–94.2
McHugh N, van den Bosch F, Manger B, Goupille P, Cooper R, Kron M, et al. Adalimumab treatment is effective in patients with psoriatic arthritis (PSA) in day-to-day clinical practice: results from the stereo trial. Rheumatology 2008;47(Suppl. 2):ii, 76.2
Mease P. Infliximab (Remicade) in the treatment of psoriatic arthritis. Ther Clin Risk Manag 2006;2(4):389–400.2
Mease PJ, Choy EHS, Atkins CJ, Sasso EH. Effectiveness of adalimumab in psoriatic arthritis patients with oligoarticular arthritis: subanalysis of ADEPT. Fourth European Academy of Dermatology and Venereology (EADV) Spring Symposium Saariselka, Lapland, Finland, 9–12 February, 2006: P-022.5
Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008;67(6):855–9.2
Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158(3):549–57.3
Rinaldi F, Provenzano G, Termini A, Spinello M, La Seta F. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response. Ann Rheum Dis 2005;64(9):1375–6.2
Ritchlin C. Efficacy and safety of infliximab for the treatment of psoriatic arthritis. Nat Clin Pract Rheumatol 2006;2(6):300–1.2
Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007;8(3):143–55.2
Saad AA, Symmons DPM, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35(5):883–90.2
Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4(4):637–41.2
Simpson D, Scott LJ. Adalimumab: in psoriatic arthritis. Drugs 2006;66(11):1487–96.2
Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008;67(11):1650–1.2
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159(2):322–30.4
Toussirot E, Streit G, Wendling D. Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov 2007;1(1):39–47.2
Van den Bosch F, Reece R, Manger B, Goupille P, Roedevand E, Holck P, et al. Adalimumab (HUMIRA (R)) is effective and safe in treating psoriatic arthritis (PsA) in real-life clinical practice: preliminary results of the STEREO trial. Arthritis Rheum 2006;54(Suppl. 9):S719–20.2
Van den Bosch F, McHugh NJ, Reece R, Cooper R, Manger B, Goupille P, et al. Treatment with adalimumab (Humira (R)) is safe and effective in psoriatic arthritis (PsA) patients in real-life clinical practice: preliminary results of the stereo trial. Rheumatology 2007;46(Suppl. 1):i,52–3.2
Van den Bosch F, Manger B, Goupille P, McHugh N, Roedevand E, Holck P, et al. Adalimumab (Humira (R)) is effective in treating patients with psoriatic arthritis (PSA) in real-life clinical practice: results of the STEREO trial [abstract OP0147]. Ann Rheum Dis 2007;66(Suppl. 2):98.2
Van den Bosch F, Manger B, Goupille P, Kron M, Kary S, Kupper H. Clinical remission and good clinical responses in patients with psoriatic arthritis (PsA) treated with adalimumab (HUMIRA (R)): results of the STEREO trial. Arthritis Rheum 2008;58(Suppl. 9):5762
Van Kuijk AWR, Gerlag DM, Vos K, Wolbink G, Zwinderman AH, Dijkmans BAC, et al. A randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial biomarkers. Arthritis Rheum 2008;58(Suppl. 9):415.2
Winterfield LS, Menter A. Infliximab. Dermatol Ther 2004;17(5):409–26.2
Winthrop KL, Siegel JN, Jereb J, Taylor Z, Lademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005;52(10):2968–74.2
a

Reasons for exclusion: 1, not relevant drug; 2, not RCT or extension; 3, not PsA; 4, no eligible outcomes; 5, unable to order.

From: Appendix 4, Table of excluded studies with rationale

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.